Leawood-based Prevail Innovative Wealth Strategies launched what it hopes will become a $100 million fund and announced its first two investments.

Prevail Venture Capital Fund I LP plans to make 20 to 35 investments, according to the Prevail website. The fund's objective is to return initial capital to investors within 36 to 42 months and generate multiples of four to five times the invested capital.

The fund looks to take a founder-first approach to investing and offer hands-on support for scaling operations, developing leadership and strategic planning. The fund targets high-potential companies in health care, technology, and consumer goods and services, particularly scalable businesses with a competitive edge.

The fund's first investment was in Cleveland-based Coologics Inc. Prevail did not disclose the amount, though it says investments can range from $250,000 to $5 million.

Coologics

Coologics was founded in 1999 by a board-certified OB/GYN with 19 years of clinical experience. The company is pioneering advancements in women's health with its flagship product Vlisse, a drug-free therapeutic solution designed with patented controlled-cooling technology.

Women deserve better solutions. With Prevail's support, we're advancing safe, non-drug therapies that have the potential to transform women's health globally.
Dr. Kim Langdon, Coologics Founder

The investment fits the fund's mission of financing entrepreneurs who are solving complex challenges with innovative approaches.

Prevail invests in ideas that challenge convention and entrepreneurs who execute with conviction. Coologics is just the beginning.
Kerry Lawing, Prevail Founder